Mersana Therapeutics Announces 1-for-25 Reverse Stock Split

Core Points - Mersana Therapeutics, Inc. announced a 1-for-25 reverse stock split effective July 25, 2025, aimed at increasing the per-share market price to comply with Nasdaq listing requirements [1][2] - The reverse stock split will reduce the number of outstanding shares from approximately 124.8 million to about 5.0 million, without changing the number of authorized shares or par value [4] - The company's common stock will begin trading on a split-adjusted basis on July 28, 2025, under the existing ticker "MRSN" [3] Company Overview - Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment, addressing high unmet medical needs [1][8] - The company has proprietary ADC platforms, including Dolasynthen and Immunosynthen, with a pipeline of product candidates targeting various cancers [8] - Notable candidates in the pipeline include Emi-Le (emiltatug ledadotin) targeting B7-H4 and XMT-2056 targeting a novel epitope of HER2 [8]